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Introduction 
This paper answers a request from the editors of the Merrifield memorial issue to place Bruce 
Merrifield and solid-phase peptide synthesis (SPPS) into historical context by considering the 
following questions.  How did such a mild-mannered and relatively unknown biochemist in the 
mid twentieth century evolve to a global chemical icon1-5 by the end of the century? What were 
the challenges and how were they met?  Was there a unique scientific life-style that exemplified 
Merrifield’s approach to research and what is his legacy?  While I did spend several memorable 
years in the Merrifield laboratory I do not claim unique insights.6 This paper derives from a talk 
given at the Merrifield Memorial Symposium at the Rockefeller University on November 13, 
2006.  It compliments contributions by Art Felix, Maurice Manning, Arnold Marglin, Garland 
Marshall, Arthur Robinson, Noah Robinson and John Stewart in this issue and hopefully adds to 
our understanding and appreciation of Bruce Merrifield. 
Historical Sources
R. Bruce Merrifield (1921-2006)
Bruce Merrifield’s scientific biography, "Life During a Golden Age of Peptide Chemistry: The 
Concept and Development of Solid-Phase Peptide Synthesis," provides a history of SPPS from 
1959 to 1993.7  While many readers will be familiar with SPPS literature after 1963, the 
inclusion of unpublished material from Merrifield’s early laboratory notebooks opens a revealing 
window on the development of SPPS from the formulation of concept in 1959 (p. 56, ref. 7) to 
the synthesis of a tetrapeptide four years later.8 Garland Marshall, Bruce’s first graduate student 
(1963-1966), as well as later colleagues, were essentially unaware of the many highways, 
byways and non-productive routes that Bruce had explored in the early years.1 Bruce had also 
provided a very personal recollection of the discovery and development of SPPS that was 
incorporated into a video, "Peptide and Protein Synthesis: Origin And Development," and shown 
at the 17th American Peptide Symposium/2nd International Peptide Symposium (June 2001, San 
Diego, CA) honoring his 80th birthday.9
Joseph S. Fruton (1912-2007)
Joseph Fruton received his Ph.D. (1934, biological chemistry) from Columbia University and 
then worked in the laboratory of Max Bergmann at the Rockefeller Institute for Medical 
Research until 1945.  He used the benzyloxycarbonyl (Z) group invented by Bergmann and 
Zervas10 to prepare synthetic peptides for the study of specificity and mechanisms of catalytic 
action of proteolytic enzymes such as pepsin.  He was until recently Professor Emeritus of 
Biochemistry and Professor Emeritus of the History of Medicine at Yale University and has an 
extensive list of journal publications (more than 330 scientific papers, reviews and monographs) 
on research in his laboratory and studies on the history of science11,12  and the interactions 
between chemistry and biology.13,14 He has also written a candid autobiography documenting 
the first 80 years of his life.15  
Peptide Synthesis Circa 1959
It is instructive to survey the world of peptide synthesis that would have been known to 
Merrifield prior to 26 May 1959, the day he recorded the concept of SPPS in his laboratory 
notebook.  Three major chemists merit discussion. 
Emil Fischer (1852-1919)
Theodor Curtius had synthesized the first known peptide derivative (benzoylglycylglycine) in 
1882.  Emil Fischer, however, beginning with the synthesis of a free dipeptide (glycylglycine) in 
1901, is credited with the first systematic attack on a field of natural substances that had been 
previously avoided by chemists. Fischer, considered by some to be the greatest chemist in the 
19th century, had conducted landmark studies in purine and carbohydrate chemistry prior to 
initiating studies in peptide and protein chemistry. The 1902 Nobel Prize in Chemistry was 
awarded to Emil Fischer "in recognition of the extraordinary services he has rendered by his 
work on sugar and purine syntheses."16 Fischer, in his Nobel lecture, compared the challenges of 
carbohydrate and protein chemistry: 
“Nevertheless, the chemical enigma of Life will not be solved until organic chemistry has 
mastered another, even more difficult subject, the proteins, in the same way as it has 
mastered the carbohydrates...the total amount of work that has to be done here is so 
enormous that in contrast the elucidation of the carbohydrates seems child’s play.”   
Notwithstanding the massive challenge that peptide and protein synthesis posed to Fischer, he 
thought that all available tools and resources should be employed (p. 125, ref. 7): 
“Whereas cautious professional colleagues fear that rational study of this class of 
compounds, because of their complicated structure and their highly inconvenient physical 
characteristics, would today still uncover insurmountable difficulties, other optimistically 
endowed observers, among which I would count myself, are inclined to the view that an 
attempt should at least be made to besiege this virgin fortress with all the expedients of the 
present; because only through this hazardous affair can the limitations of the ability of our 
methods be ascertained.”
Fischer’s optimism was reflected a year earlier (1905) in a letter to Adolph von Baeyer: 
“My entire yearning is directed toward the synthesis of the first enzyme. If its preparation 
falls into my lap with the synthesis of a natural protein material, I consider my mission 
fulfilled.”
Fischer’s progress in peptide synthesis was hampered by the lack of reversible protecting groups.  
Nevertheless, his use of the haloacyl method yielded an octadecapeptide containing three amino 
acids.17
Max Bergmann (1886-1944)
Max Bergmann completed his doctoral dissertation in Fischer’s laboratory (1911) and became an 
assistant to Fischer until Fischer’s death in 1919.  He was director of the Kaiser Wilhelm 
Institute for Leather Research in Dresden from 1922-1933 and during this period Bergmann, 
with his student Leonidas Zervas, invented the benzyloxycarbonyl (Z) group for the reversible 
protection of amino groups.10 The careers of Jewish scientists in Germany virtually ended with 
the creation of the Nazi state in 1933. Bergmann immigrated to the United States in 1934 where 
he headed a laboratory at the Rockefeller Institute for Medical Research until his early death 
from colon cancer in 1944.  Zervas had followed Bergmann to the Rockefeller Institute where a 
talented group of postdoctoral associates that included Joseph Fruton, Klaus Hofmann, Stanford 
Moore and William Stein was assembled.  Fruton, initially tutored by Zervas in peptide 
synthesis, used the Z group to prepare numerous peptide substrates for specificity studies on a 
variety of proteolytic enzymes (p. 41, ref. 15).  Bruce was very much aware of Bergmann’s work 
performed at the Rockefeller Institute for Medical Research prior to his arrival and felt honored 
to work in the same laboratory space that Bergmann had occupied (personal communication, Dr. 
Ulf Ragnarsson).  He was especially proud to have inherited Bergmann’s office and desk. 
Vincent du Vigneaud (1901-1978)
Vincent du Vigneaud’s career spanned nearly 50 years with a focus on sulphur-containing 
compounds of biochemical importance including insulin, penicillin, and hormones of the 
posterior pituitary gland (oxytocin, vasopressin).  A series of lectures presented at Cornell 
University, “A Trail of Research in Sulphur Chemistry and Metabolism and Related Fields,” 
describe his meticulously designed and executed research from the late 1920s into the early 
1950s.18 Du Vigneaud’s move to Cornell University Medical College as Head of the 
Biochemistry Department in 1938 placed him next door to the Rockefeller Institute for Medical 
Research on the upper east side of Manhattan (New York City).  This close proximity gave du 
Vigneaud, son of an inventor and machine designer, early access to research tools developed at 
Rockefeller that would later prove invaluable in the structure determinations and subsequent 
syntheses of oxytocin and vasopressin.  The invention of countercurrent distribution (CCD) by 
Lyman Craig (1906-1974) made possible the isolation and purification of antibiotics, peptide 
hormones (oxytocin, vasopressin, ACTH, MSH, HGH), proteins (TMV protein, ribonuclease, 
hemoglobin a and b chains) and transfer RNA.19,20 Stanford Moore (1913-1982) and William 
Stein (1911-1980) continued the work of the Bergmann laboratory at the Rockefeller Institute for 
Medical Research and developed the first reliable and sensitive amino acid analysis of peptides 
and proteins.  All of the naturally occurring amino acids from mammalian sources were initially 
resolved by chromatography on starch columns with a more rapid chromatography later achieved 
by ion exchange chromatography.21
Although du Vigneaud began receiving nominations for a Nobel Prize as early as 1943 
(physiology or medicine) and 1944 (chemistry), it was not until his landmark work on the 
structure and synthesis of oxytocin reported in 1953 that the Royal Swedish Academy of 
Sciences decided that the 1955 Nobel Prize in chemistry should be awarded to du Vigneaud.22 A 
few points regarding these nonapeptide hormones from the pituitary gland should be noted.  The 
isolation of highly purified oxytocin needed for structural studies was made possible with the 
CCD apparatus developed earlier by Lyman Craig at the neighboring Rockefeller Institute for 
Medical Research.19,20 As structure determinations of peptides in the 1950s precluded the use of 
modern instrumentation (HPLC, mass spectrometry, high resolution NMR), careful degradative 
studies, coupled with accurate amino acid analyses, led to a proposed structure for oxytocin 
which featured a nonapeptide amide containing a disulfide bridge.23 The synthesis of such a 
structure in 1953 was formidable task and it was far from obvious how to synthesize a molecule 
with a disulfide bridge that forms a 20-atom ring containing six of the nine residues present in 
the molecule.  Wieland and Bodanszky have discussed the details of the first and subsequent 
syntheses of oxytocin.24 The use of CCD, successfully employed in the isolation of the natural 
product, proved invaluable in the purification of synthetic oxytocin.  The overall yield in the first 
synthesis of protected nonapeptide by fragment condensations and its conversion to pure, 
biologically active oxytocin was well under one percent.  Subsequent workers improved the 
overall yields of oxytocin to 5-10% employing fragment condensations.  Bodanszky and du 
Vigneaud employed p-nitrophenyl esters of carbobenzoxy-aminio acids to synthesize oxytocin in 
stepwise manner starting from the C-terminal residue.  This new strategy maintained optical 
purity during the peptide bond-forming reactions which afforded oxytocin in 38% overall yield.25
Challenges in the Development and Acceptance of SPPS
We can assume that Merrifield was aware of the work discussed above as well as other 
publications.  The synthetic peptide community and its synthetic literature were not so large as to 
be unmanageable in the 1950s.  Merrifield arrived at the Rockefeller Institute for Medical 
Research in 1949 after graduate training in biochemistry and microbiology under Max Dunn at 
UCLA.  His work in the laboratory of Dr. D.W. Woolley on the structural characterization of 
peptide growth factors (strepoginins) eventually led to a need for the chemical synthesis of 
strepoginin peptides.  In describing the solution synthesis of a pentapeptide (Ser-His-Leu-Val-
Glu) Bruce remarked that “my overall yield of pentapeptide was 7%, and it took me 11 months.  
Certainly, an experienced peptide chemist would have done better, but not without considerable 
effort.” (p. 53, ref. 7).  Certainly, in Bruce’s mind there was a clear need for a more efficient and 
rapid synthesis of peptides. 
Bruce Merrifield had to address three major challenges related to development and acceptance of 
SPPS.  The interrelated challenges were (1) to reduce the concept of peptide synthesis on a 
insoluble support to practice, (2) overcome the resistance of synthetic chemists to this novel 
approach and (3) establish that a biochemist had the scientific credentials to effect the proposed 
revolutionary change in chemical synthesis.  How were these challenges met? 
Peptide Synthesis on an Insoluble Support (1959 – 1984)
The use of an insoluble polymer covalently linked to a growing peptide chain was without 
chemical precedent when Bruce began his studies on SPPS in 1959.  While a vast literature on 
the preparation and modification of polymers was known, no one had reported using polymer 
supports for the synthesis of other classes of compounds.  Although Bruce did not recall exactly 
when he had the idea for SPPS, its genesis was in his words “obviously a result of having 
recognized a distinct need and of having thought about the general problem for some weeks.  I 
also think it was in large measure a result of having been close to the earlier peptide work in an 
experimental sense.  Because I had done all of the laboratory work myself, I could visualize from 
direct experience what could be done and what needed to be done (p.55, ref. 7).”
Christian Birr speculates in his monograph, “Aspects of the Merrifield Peptide Synthesis,” that 
Merrifield’s idea for SPPS was influenced by the ribosomal biosynthesis of proteins.26 However, 
the N- to C- sequential biosynthesis of proteins on ribosomes (Merrifield SPPS proceeds in a C-
to N-direction) and was not reported by Howard Dintzis until the early 1960s.  On a human 
interest note, Dintzis recalled taking an advanced biochemistry course at UCLA in the 1940s and 
remarked that “the laboratory part of that course was excellent, having as teaching assistant a 
remarkable graduate student: Bruce Merrifield, who later won a Nobel Prize for devising solid 
state peptide synthesis.”27
Continuing in a speculative vein, a more obscure precedent for SPPS was recently found in a 
patent search by this writer, namely “Improvements in and Relating to Polyamides Derived from 
a-Amino Acid N-Carboxyanhydrides” published in 1957 in Great Britain by Basil Alexander 
Ripley-Duggan (Patent Specification, Dec. 4, 1957, GB787,344 ). Briefly stated, a soluble 
aminopolystyrene (linear, non-crosslinked) was prepared and reacted in benzene with the N-
carboxyanhydride of DL-valine to afford a block copolymer containing 24-9% polystyrene and 
76-91% polypeptide.  This material dissolved only in m-cresol and displayed good thermoplastic 
properties. Interestingly, many years later, Sarin and Kent used a step-wise approach to prepare 
peptide-polystyrene supports containing up to 60 amino acid residues (80% peptide content) in a 
study of synthetic efficiency in SPPS as a function of growing chain length.28 The observation 
of high synthetic efficiency at 60 residues and 80% peptide content on a 1% crosslinked 
polystyrene support demonstrated the lack of intrinsic limitations to stepwise solid-phase 
synthesis over an extreme range of peptide loading.  This was, of course the state of perfection of 
SPPS in 1984, not 1959.
Regardless of what conscious and unconscious forces were at play, when Bruce formally 
described the concept of SPPS in his laboratory notebook on May 26, 1959, the most trying 
period in his scientific life was to begin.  The search for a suitable support and appropriate 
chemistry that was originally planned to take 3 months consumed 3 years with Bruce later 
reflecting, “At the end of the first two years the results were so poor, I wonder what made me 
think that this approach would ever succeed. I have always been grateful to Dr. Woolley for 
giving me the freedom in his laboratory to pursue the problem to the end and to the
Rockefeller University for supporting me through the long nonproductive period (p. 90, ref.7 )”.  
He also noted  “When I look back at my old notebooks, I am amazed at how inefficient the early 
developmental work was. I seemed always to choose the wrong reaction to do first and was not 
able to identify the most important parameters as the work was progressing. (pp. 89-90, ref.7 ).”  
The first successful synthesis of the tetrapeptide Leu-Ala-Gly-Val by SPPS was described at 
the  meeting of the Federation of American Societies for Experimental Biology in 1962 with a 
full paper appearing in 1963.8 The response of non-specialists (scientists employing peptides in 
biological investigations) was quite enthusiastic while the specialists (synthetic peptide chemists) 
seemed dismayed.  The idea of conducting a multi-step synthesis, no matter what forcing 
conditions were employed, without isolating, purifying and characterizing intermediates was 
clearly beyond the pale. 
Certainly, no self-respecting peptide chemist was going to abandon classical, solution techniques 
and adopt SPPS as described in the 1963 paper. However, for Bruce, the diligent optimist, the 
corner had been turned.  The concept of step-wise peptide synthesis on an insoluble matrix had 
been demonstrated.  Now it was time to synthesize larger, more complex peptides using SPPS. 
Recall that the test tetrapeptide Leu-Ala-Gly-Val was the result of 3 years of slow progress 
interrupted by numerous setbacks. Now, with more appropriate chemistry becoming available, 
the pace quickened.  Replacement of NaZ- with Na-Boc-protecting groups and use of an 
unsubstituted 2% cross-linked polystyrene resin in place of the originally employed 
nitropolystyrene support allowed the preparation of fully active and chromatographically pure 
bradykinin (nonapeptide) in 32% yield in 8 days. A subsequent, improved synthesis, provided 
bradykinin in 68% yield. Garland Marshall, Bruce’s first graduate student, joined the Merrifield 
group at this time with the task of synthesizing the octapeptide hormone angiotensin II.  Garland
contrasted this goal with the efforts of Vincent du Vigneaud and a large team of synthetic 
chemists ten years earlier that resulted in the synthesis of two nonapeptide hormones (oxytocin 
and vasopressin) and a Nobel Prize for du Vigneaud (vide supra).  In Garland’s words “ Here I 
was, just ten years later, trying to synthesize an octapeptide hormone, angiotensin II by myself, a 
naïve graduate student, with a totally novel approach.”29 Garland, of course, succeeded and a 
series of increasingly larger, biologically active peptides were prepared over the next three years 
(1964-1967) in the Merrifield laboratory culminating with bovine insulin.30  The arrival of Bernd 
Gutte, Bruce’s first postdoctoral fellow, from Germany (1967) provided the opportunity to push 
existing SPPS methodology to the limit and undertake the synthesis of the 124-residue enzyme 
RNase A. In early 1969 Bernd Gutte and Bruce Merrifield published the use of SPPS to achieve 
the total synthesis of an enzyme with RNase A activity.31 This achievement, coupled with a 
similar effort by the Merck group using classical solution chemistry32  attracted global attention 
in the scientific and popular press.
By the early 1970s it had became apparent that the solid-phase synthesis of RNase A could not
be generalized.  Consequently, virtually every aspect of SPPS was reexamined and improved 
during the decade of the 1970s (pp. 151-179, ref. 7).  The sensitive detection and elimination of 
possible side reactions (amino acid insertion, Na-trifluoroacetylation, Nae-alkylation) was 
examined.  An optimization of the HF cleavage reaction based on an understanding of the 
mechanism was developed.  The quantitation of coupling efficiency in SPPS as a function of 
chain length was studied. A new and improved support for SPPS, the “PAM-resin,” was 
prepared and evaluated. In addition to considerable methodological work on SPPS, parallel 
synthetic efforts on biologically active peptides such as glucagon, thymosin a1, epidermal 
growth factor and antimicrobial peptides were undertaken (pp. 180-195, ref. 7). These and many 
other studies from the Merrifield laboratory and elsewhere increased the general acceptance of 
SPPS.
 
The success of SPPS dramatically influenced the chemical synthesis of DNA.33  The chemical 
synthesis of DNA had been extremely laborious and time-consuming prior to the development of 
solid-phase syntheses of DNA.  For example, the preparation of a lac operator (a 21 base paired 
DNA duplex) required the equivalent of four years of highly skilled and intense effort.  When the 
appropriate chemistry (phosphoramidite method of DNA synthesis) and support were 
discovered, the rapid preparation (≤ 1 day) of deoxyoligonucleotides the size of a lac operator 
became possible. Use of automated DNA synthesis machines now leads to very high yields of 
relatively pure polynucleotides having 100 or more mononucleotides.33 In retrospect, it seemed 
likely that Bruce would receive validation from Stockholm.  The decisions of the Nobel 
Committee are not obvious, however.22 To the great delight of friends and colleagues the call 
came on October 17, 1984 with the decision to award the 1984 Nobel Prize in Chemistry to 
Bruce “for his development of methodology for chemical synthesis on a solid matrix.”16
Resistance and Acceptance of Chemical Synthesis on a Solid Matrix
Merrifield first described the synthesis of the tetrapeptide Leu-Ala-Gly-Val by SPPS at the 
annual meeting of the Federation of the American Societies for Experimental Biology (FASEB) 
in the spring of 1962.  He recalled that two “peptide experts” were sitting in the front row of the 
audience.  One of the experts was Professor Joseph Fruton, certainly the doyen of American 
peptide chemistry at that time (vide supra).  Fruton expressed his displeasure by stating “this is 
not the way to synthesize peptides.”34 A full paper describing the concept of SPPS and synthesis 
of the tetrapeptide was submitted in early 1963.8 One of the reviewers characterized this new 
approach as a “travestry, …not chemistry at all, a concept which should be suppressed by the 
community.”29  Garland Marshall recalled the early  “vehement and vitriolic” critics in his 
discussion of SPPS as a paradigm shift.1 He also recalled collecting “a fair bit of psychological 
scar tissue, as did  Bruce, in spreading the gospel of this paradigm shift in chemistry.”  Max 
Brenner essentially summarized the early criticism of SPPS in 1973 by dyspeptically stating: 
“The invention of the solid-phase method looked like an ingenious trick to overcome some of the 
unpleasant features of the classical methods.  As we know today, the ingenuity of the trick 
remains, but only a large investment of heavy real effort will eventually, if ever, work it into a 
real progress over the classical approach.”35  
The early negative receptions from peers, eminent and otherwise, would have dissuaded the 
weak-kneed among us but not one with the constitution of Bruce Merrifield.36 Even in his 
darkest hours, he did not waver and it bears repeating:  “At the end of the first two years the 
results were so poor, I wonder what made me think that this approach would ever succeed.  But 
from the outset I had a strong conviction that this was a good idea, and I am glad that I stayed 
with it long enough”. (p.90, ref.7).
The bradykinin syntheses37,38 provided the demarcation  between 3+ years of developmental 
work in SPPS and the ability to produce other biologically active peptides of similar size and 
complexity.  However, for SPPS to be accepted, it was essential to have validation from 
scientists grounded in synthetic organic chemistry.  Fortunately, John Stewart joined the Woolley 
group in 1952 after completing his doctoral research in synthetic organic chemistry with Roger 
Adams at the University of Illinois.  Bruce and John and their families became good friends. In 
“Remembering Bruce: The Early Years ”39 John recalls during the developmental work on SPPS:
“Bruce and I had spent long hours discussing the problems, failures, and possible improvements. 
Since the problems were a specialized form of organic chemistry and I was a trained organic 
chemist, I was able to make useful suggestions. When yet another experiment failed, Bruce 
would declare that he was going to quit and open a gasoline station on a road in the Arizona 
desert; Bruce had a great love for the southwest American desert. Fortunately he never carried 
through on that threat!”  In research with Dr. Woolley starting in 1962 John began synthesizing 
analogs of bradykinin in a search for antagonists.  The syntheses employed standard solution 
peptide synthesis methods and in one year he synthesized three bradykinin analogs.  Bruce’s 
success in preparing bradykinin by SPPS led John to adopt SPPS and in the next year he was 
able to synthesize nearly fifty analogs. This fully convinced Stewart that SPPS would be an 
incredible improvement for the general synthesis of peptides.39
During this period (1961 - 1964) Maurice Manning, an organic chemist and Fulbright Travel 
Grantee from Ireland, was a city block away in the du Vigneaud laboratory (Cornell Medical 
College) learning to make peptides by solution methods.  Manning synthesized three analogs of 
oxytocin in three years and learned what huge resources, in terms of manpower, equipment and 
supplies were required to sustain the highly successful research program on the 
neurohypophysial peptides in the du Vigneaud laboratory.  Manning then spent a year learning
the recently developed SPPS from Merrifield in the Woolley laboratory at the Rockefeller 
University (1964 -1965).  The remainder of the story as recounted by Manning in “Impact of the 
Merrifield Solid Phase Method on the Design and Synthesis of Selective Agonists and 
Antagonists of Oxytocin and Vasopressin: a Historical Perspective,” is a magnificent research 
tour de force.40 Briefly stated,  Maurice Manning’s synthesis of oxytocin by SPPS opened the 
way for him to conduct monumental research on the design and synthesis of selective agonists, 
antagonists and radioiodinated ligands for oxytocin and vasopressin receptors over a 40 year 
period without requiring the vast resources and manpower available to large academic and 
industrial laboratories.
While no one had claimed quantitative (100%) coupling efficiencies in SPPS, the efforts of 
Merrifeld, Stewart, Manning, Marshall and others demonstrated during the 1960s that SPPS (in 
combination with purification techniques then available) was fully capable of efficiently 
producing 10-residue peptides indistinguishable from the corresponding natural products or 
peptides prepared by solution methods.  Nevertheless, the concept of a multi-step synthesis 
without the isolation and purification of intermediates was an anathema to most synthetic 
chemists.  What then would be the prognosis for the preparation of peptides containing 30 amino 
acids? The synthesis of mammalian glucagon, a 29-amino acid peptide hormone secreted by the 
pancreas, was considered a landmark achievement when Erich Wünsch and coworkers described 
the preparation of fully active, crystalline material in 1968.41 The synthetic glucagon was 
prepared in solution using classical fragment condensation methods by a large, skilled team over 
a period of several years.42 Wünsch reviewed the synthesis of naturally occurring polypeptides 
and reflected on the problems of synthetic peptide research circa 1971.43 Using the glucagon 
synthesis as a model, he contended that conventional (solution) synthesis would be considered 
very good for the synthesis of peptide sequences containing up to 30 amino acid residues and, 
barring solubility problems, the maximum sequence possible would be 30-50 amino acid 
residues. Wünsch did not entertain the prospect of examining structure-function relationships in 
glucagon using solution synthesis for the production of analogues.  The cost, of course, would be 
astronomically prohibitive in terms of manpower and resources. A large portion of the review is 
devoted to SPPS, which exhibits "inborn defects" with respect to peptide synthesis and 
inadequacy of analytical methods to monitor synthetic progress. Wünsch concluded that SPPS in 
1971 was "unsuitable for the satisfactory synthesis of higher natural peptides (with more than 15 
amino acid residues)."
However, as stated earlier, virtually every aspect of SPPS was reexamined and improved during 
the decade of the 1970s (pp. 151-179, ref. 7). The first synthesis of mammalian glucagons by 
SPPS by Svetlana Mojsov, a graduate student in the Merrifield laboratory, was briefly described 
in 1977 as part of a report on recent developments in SPPS.44 The detailed synthesis that was 
reported later described the preparation of fully active, crystalline glucagon using an 
alkoxybenzyl alcohol resin (Wang resin) with the biphenylylisopropyloxycarbonyl group (Bpoc) 
used for temporary a-amino protection.45 The crude synthetic material was purified by gel 
filtration and ion-exchange chromatography followed by crystallization of the 29-residue 
hormone from aqueous solution at pH 8.8.  The synthetic glucagon was homogeneous and 
indistinguishable from natural bovine glucagon by gel electrophoresis, ion-exchange 
chromatography, fluorescence spectroscopy, amino acid analysis and it was fully active in the 
rabbit hyperglycemia assay.
An improved synthesis of crystalline mammalian glucagon was subsequently developed by 
Mojsov using a PAM resin with Na-t-butoxycarbonyl and benzyl-based side-chain protection for 
most of the trifunctional amino acids.46 The newly developed cyclohexyl-protecting group was 
used for the b-carboxyl of aspartic acid to minimize aspartimide formation.47 Cleavage of the 
29-residue peptide from the resin using an improved HF procedure48 provided crude synthetic 
glucagon in 75% yield.  A one-step purification using preparative C18 reverse-phase 
chromatography gave pure material (48% overall yield), which was crystallized from aqueous 
solution at pH 9.2.  The overall 48% isolated yield of homogeneous glucagon based on the 
starting C-terminal residue is much higher than the yield obtained in the earlier stepwise solid-
phase synthesis of glucagon in which more acid-labile protecting groups were used.45 It is also 
higher than the yield reported for synthesis by solution methods.41,42 The high yield obtained in 
the synthesis and the subsequent ease of purification of synthetic glucagon made it feasible for 
the first time to approach structure-function studies of the glucagon molecule through the total 
synthesis of selected analogues in a rapid and cost-effective manner.   
Over 200 analogues (agonists, antagonists) of glucagon had been synthesized in the Merrifield 
laboratory by 2006. An overview of research probing the glucagon receptor has been provided 
by Cecilia Unson, Bruce's long-term collaborator and colleague for 28 years.49 Presently, a 1 to 
2 person-week of effort is required for the preparation and purification of a glucagon analogue 
using the chemistry outlined above.50  Again, to belabor the very obvious, a comparable study of 
structure-function relationships based on the availability of glucagon analogues from solution 
synthesis41,42 is unthinkable with respect to manpower, cost and time required.  This is precisely 
why Bruce Merrifield invented SPPS and his colleagues labored to improve upon the 
method as originally conceived.6
What about the SPPS of peptides larger than glucagon, say 90 to 100 residues?  Mitchell and co-
workers developed a more acid stable PAM resin support51-53 and Kent and co-workers improved 
the synthetic protocols used with PAM resins and introduced in situ neutralization into SPPS 
using Boc/Benzyl chemistry for the rapid, efficient synthesis of difficult sequences.54 In 
addition, several side reactions were examined and eliminated.  The improved chemistry and 
protocols were utilized in the synthesis of the L and D enantiomers of the 99 residue HIV-1 
protease (1-99).55 Whether PAM resins with more improved chemistry can be routinely 
employed for the synthesis of peptides ≥ 90 to 100 residues remains to be established.  However, 
the development of native chemical ligation (NCL) methods using C-terminal peptide-thioesters 
(obtained from SPPS) that can be coupled together without side-chain protection has provided 
strategies for the synthesis of larger peptides (> 100 residues).56,57 Recently, Torbeev and Kent 
reported the convergent chemical synthesis of a 203 residue "Covalent Dimer" of HIV-1 protease 
enzyme using NCL methods.  The resulting enzyme molecule showed full catalytic activity and a 
high resolution crystal structure was reported.58
Tom Muir has provided an exciting extension of the NCL approach by using recombinant DNA 
techniques to produce the C-terminal peptide-thioesters employed in NCL.  This approach, 
termed expressed protein ligation (EPL), is an amalgamation of SPPS and ribosomal peptide 
synthesis.59 It affords the semi-synthesis of large proteins and allows site-specific introduction 
of unnatural amino acids and biophysical probes into these proteins.  Martin Engelhard recently 
described the use of EPL for the semi-synthesis of H-Ras protein (166 amino acids). A glutamic 
acid methylester residue was replaced by glutamine at position 61 to probe the role of Gln61 in 
the catalysis of GTP hydrolysis reaction by Ras protein.60
We have traveled almost 50 years from Bruce’s formulation of the concept of SPPS to the 
chemical synthesis of uniquely labeled proteins using combinations of SPPS, NCL and EPL.  
This was made possible through the continuing dedication of Bruce Merrifield and colleagues to 
improve SPPS. Even near the end of his life, with a progressively debilitating illness and 
invasive medical treatments taking their toll, Bruce in his 80s was designing experiments to 
analyze and minimize reactions that lead to deletion peptides in SPPS.61 The early criticisms of 
SPPS, mostly addressed over the years and now forgotten, reside in the dustbin of peptide 
history. 
Biochemistry and the Legacy of “Tierchemie ist Schmierchemie”
To answer the question of how can a biochemist create a revolutionary change in the approach to 
chemical syntheses, we need to first consider the interplay between biochemical and chemical 
research in the 19th century.  The famous German chemist, Justus von Liebig (1803 – 1873), 
made seminal contributions to agricultural, biological and organic chemistry in addition to 
training a great number of students that influenced the course of organic chemistry in 19th
century Germany (pp.16-71, ref. 11).  There was great interest in the English translation of 
Liebig’s  “Die Organische Chemie in ihrer Anwendung auf Physiologie und Pathologie” under 
the title “Animal Chemistry or Organic Chemistry in its Application to Physiology and 
Pathology,” both published in 1842 (p. 64, ref.14).  The interdisciplinary approach of Liebig in 
the mid-19th century gave way to a transformation of the theoretical and practical style of organic 
chemical research by 1900, with an emphasis on the proof of structure through synthesis.  This 
accentuated the separation of the organic or “pure” chemists from physiological chemists or 
biochemists.  As the physiological chemists then lacked the tools to investigate the constitution 
and dynamics of living systems to match the standards of the new organic chemistry, the widely 
quoted saying, “Tierchemie ist Schmierchemie”: Animal chemistry is messy chemistry, evolved 
(p. 57, ref.14).  Emil Fischer also shared this disdain. In a letter to a colleague in 1904 Fischer 
wrote: “Regrettably, biological chemistry is that part of our science in which imprecise and 
incomplete experiments are often padded with the dazzling ornamentation of so-called ingenious 
reflections to produce pretentious treatises (p. 64, ref.14).”  It should be noted in this context that 
Otto Warburg (1883-1970), Nobel Laureate (1931, Physiology) and perhaps the most prominent 
biochemist of the 20th century, received his doctorate from Emil Fischer in 1906 for the first 
synthesis of optically active peptides using the halogenacyl halide method ( pp. 208-210, ref.11).  
Frank Westheimer (1912 -  2007) was an eminent professor at Harvard University, a key figure 
in 20th century chemistry and a pioneer in investigating biochemical problems using physical 
organic principles.62 He reflected in an essay titled “Musings” that the German dogma stating 
that “Tierchemie ist Schmierchemie” or “biochemistry is sloppy chemistry” (Westheimer’s 
translation) seemed to be alive and well into the 1960s due to the tight compartmentalization of 
chemists.63  Organic chemists did not read the biochemical literature or attend biochemical 
seminars. A colloquium set up for Westheimer’s students and those of another professor in the 
chemistry department at Harvard quickly divided along an imaginary line between chemists and 
biochemists.
Max Brenner, in an essay titled “Need for Solid-Phase Thinking in Solid-Phase Synthesis,” 
characterized the solid-phase method as an “ingenious trick” that would never really be able to 
compete with the classical (solution) approach to peptide synthesis.35 To directly quote Brenner: 
“Euphoria seized biochemists and others: disappearance of the solubility problem and of the 
isolation problem meant disappearance of the yield problem, because quantitative yield now 
looked merely like a matter of simple mass action!”   In other words this “ingenious trick” to 
overcome the disadvantages of classical synthesis could only have been conjured up by a 
biochemist and, of course, only biochemists and their ilk would subscribe to this nonsense –
shades of “Tierchemie”? 
How is it that a biochemist, and not an organic chemist invented a technique that has broad and 
growing applications in many areas of synthetic chemistry?  Garland Marshall recalls after the 
publication of Bruce’s first paper in 1963 a “steady stream of prominent scientists visited the 
laboratory. Almost each one mentioned at some point in the visit how he had thought of using a 
filterable polymeric support as a protecting group (the essence of solid phase synthesis), but, of 
course, none had spent the years exploring alternative approaches until a practical solution was 
found.”29 Bruce’s problem was analogous to the problems physiological chemists faced almost a 
century earlier – the study of complex systems but lacking the necessary tools.  Bruce, like his 
predecessors, was undaunted by complexity and worked for three years to prepare a 
tetrapeptide.8  However, the concept of a multi-step synthesis without the isolation, purification 
and characterization of intermediates was akin to the “Schmierchemie” of an earlier era to some 
synthetic chemists.  Bruce, a man modest in demeanor but strong in character, looked beyond the 
early criticism and ridicule and pushed on. The rest, of course, is history (7).  It is the supreme 
irony that the latest advance in the chemical synthesis of proteins, namely Expressed Protein 
Ligation59, is an amalgamation of SPPS (invented by a biochemist) and ribosomal peptide 
synthesis (discovered by biochemists).
Scientific Style of the Merrifield Research Group
Joseph Fruton, in his monumental “Contrasts in Scientific Style.  Research Groups in the 
Chemical and Biochemical Sciences,” begins with Justus Liebig's group at Giessen.11 This is 
followed by analyses of other prominent German chemical (Adolf von Baeyer, Emil Fischer) and 
biochemical research groups (Felix Hoppe-Seyler, Willy Kiihne, Franz Hofmeister) in the period 
1830-1914. Biographical details of each leader's scientific progeny fill seven appendices.  Such 
an analysis of the Merrifield research group is clearly beyond the scope of this paper.  Garland 
Marshall has described the hierarchical system in place at Rockefeller when he entered the 
Woolley laboratory to work with Merrifield in 1963.29 Each research group was organized under 
the leadership of a Professor in a pyramidal/Prussian manner. Prof. D. Wayne Woolley was a 
founder of the field of antimetabolites and had two junior faculty (Merifield and Stewart) 
working in his group as well as postdocs, graduate students and technicians.  Merrifield became 
head of the laboratory when Woolley died in 1966 and John Stewart moved to the University of 
Colorado Medical School in 1968.
The scientists discussed in Fruton’s treatise are multi-faceted as in the case of Emil Fischer, for 
example.  On the one hand, Fischer could be dictatorial and demanding:
“With a stern eye he inspected the laboratory workers, who reported to him the progress of their 
experiments.  Fearsome was his Flügelschlagen [flapping of wings], without further comment, 
for the poor wretch if something had gone thoroughly wrong.  Only rarely did the chief sit on a 
stool and conduct a brief private conversation.  Then it was even permissible to laugh.  However, 
the slightest attempt at intimacy would terminate the conversation immediately (p. 171, ref.11)”
On the other hand, Fischer treated the foreign visitors in his laboratory more kindly. The 
American physician Herrick, who worked in Fischer’s laboratory in 1905, described him as 
follows:
“He was modest, kindly, always the gentleman.  Twice a day he made the rounds, moving 
quietly from desk to desk inspecting the work, always seeming interested, criticizing, helpfully 
suggesting.  He had the faculty of seeing quickly where one’s trouble lay.  So gentle in manner 
was he that one scarcely realized he was a good executive commanding officer (p.172, ref.11 ).” 
When Garland Marshall began his thesis research across the bench from Bruce he noted: 
“Although I had the illusion that I was working independently, Bruce obviously was a dominant 
influence by his logical approach to all experimental questions, discussed regularly across the 
bench top.  Bruce was a superb experimentalist who designed experiments that unambiguously 
focused on the question to be resolved.”29
Bruce was the antithesis of the dictatorial and demanding laboratory head.  I would in fact 
characterize his leadership as minimalist and non-intrusive. Bruce was always accessible and the 
only requirement he had was that each graduate student and postdoctoral research associate work 
on a project of mutual interest (mainly to fulfill grant requirements) with as much freedom as 
they were willing to accept. The arrivals in Bruce’s laboratory after 1963 accepted SPPS, with its 
early imperfections, as a fait accompli that we used and/or improved upon with time.6 Although 
Bruce’ s early notebooks were available to all in the laboratory, I can’t recall discussions on the 
early difficulties and setbacks as Bruce, always the quintessential optimist and forward looking 
scientist, was more focused on the future than the past.  However, when one had problems even 
remotely related to any aspect of SPPS, he was very open to discussing the problem, its 
significance and possible solutions.  
Fruton says little how the personal lives of his subjects influenced their scientific lives.  The 
Merrifield that his colleagues knew and respected, was tough and dedicated but also caring and 
modest.  He deeply cared about his two families, the family at home and the family in the 
laboratory (pp. 208-227, ref. 7).  This genuine, deep-seated outlook and civility enabled us to do 
the best work we were capable of.
Scientific Legacy of R. Bruce Merrifield
Bruce Merrifield’s original intent was simply to make the task of peptide synthesis less onerous.  
He could not have imagined, especially in the early years, that his work would result in a 
paradigm shift in synthetic chemistry.1  Solid-phase synthesis as used for the synthesis of 
biopolymers (peptides, proteins, nucleic acids), synthesis of natural products, chemical ligation 
and materials development has indeed provided a paradigm shift in the molecular biology, 
biotechnology and chemistry communities.  Also, the impact of solid-phase synthesis on 
combinatorial chemistry, a field not yet conceived, could not have been predicted in 1959. 
Merrifield’s influence on his scientific progeny, and their progenies, is also a part of his 
scientific legacy.  His generous acknowledgements of colleagues and their work in his biography 
should serve as a model for others.  Finally, even in the competitive world of science, to quote 
Garland Marshall one last time, “Bruce serves as a perfect example of the encouraging fact that 
good guys can finish first.”29
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